Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain [0.03%]
Elranatamab与当前疗法管理三线暴露、复发和难治性多发性骨髓瘤患者的成本效益，包括其他双特异性药物以及西班牙医生选择的治疗方案的成本效益分析
Cristina Encinas,Virginia Lozano,Patrick Hlavacek et al.
Cristina Encinas et al.
Introduction: Elranatamab is a bispecific anti-B-cell maturation antigen (BCMA) and -CD3 antibody recently approved in Spain for the treatment of adult patients with triple-class exposed relapsed and refractory multiple m...
The Utilization of Specialist Palliative Care and Other Health Care Services at the End of Life Among Patients with Head and Neck Cancer: A Nationwide Cohort Study [0.03%]
头颈部癌症患者生命末期专科姑息治疗及其他医疗服务的利用情况——一项全国队列研究
Martti Merikari,Outi Akrén,Mikko Nuutinen et al.
Martti Merikari et al.
Introduction: The end of life of patients with head and neck cancer (HNC) is plagued by significant morbidity and high symptom burden, emphasizing the need for palliative care. Our aim was to evaluate the utilization of h...
Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast [0.03%]
晚期肾细胞癌的共享决策：关注阿昔替尼联合免疫检查点抑制剂不良事件管理：vodcast系列
Edwin M Posadas,Nancy Moldawer,Greg Biddulph et al.
Edwin M Posadas et al.
Shared decision-making is essential to the care of patients with advanced renal carcinoma which can empower patients and help the healthcare team understand the patient's goals of care. An important topic during the shared-decision making p...
A US Survey Across Seven Early-Stage Cancers Assessing the Humanistic Burden of Recurrence on Patients and Caregivers [0.03%]
对患者和护理者因七种早期癌症复发而产生的人文负担的美国调查研究
Raquel Aguiar-Ibáñez,Kelly McQuarrie,Ana Martinez et al.
Raquel Aguiar-Ibáñez et al.
Introduction: Patients diagnosed with an early-stage cancer are at risk of recurrence. Although the economic burden of a cancer recurrence is described in the literature, little is known about the humanistic burden of an ...
Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management [0.03%]
Venetoclax治疗新诊断急性髓系白血病的现实世界经验（日本VENUS研究）：着重于中性粒细胞减少症管理的中期分析
Tatsunori Goto,Hiroki Numata,Yuna Katsuoka et al.
Tatsunori Goto et al.
Introduction: Venetoclax has demonstrated clinical benefit for newly-diagnosed acute myeloid leukemia (AML), but significant neutropenia is a concern. Data on the time course of neutrophil counts for across treatment cycl...
Oncological Management of Adrenocortical Carcinoma: An Update and Critical Review [0.03%]
肾上腺皮质癌的肿瘤学管理：更新和批判性评论
Nicholas P Rowell
Nicholas P Rowell
Adrenocortical carcinoma is a very rare cancer that commonly presents with hormonal abnormalities or, more rarely, as an incidental finding of an adrenal mass. Following optimal surgical management, ideally in the form of open adrenalectomy...
Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan [0.03%]
日本转移性雄激素敏感性和雄激素难治性前列腺癌治疗的医师和患者偏好：一项最佳-最差分类研究
Takahiro Kimura,Noriko Takahashi,Keiko Asakawa et al.
Takahiro Kimura et al.
Introduction: Despite many prostate cancer (PC) treatment options in Japan, physicians' and patients' preferences in metastatic castration-sensitive PC (mCSPC) and castration-resistant PC (CRPC) are unclear. ...
The Impact and Performance of the Molecular Tumor Board: Three-Year Activity in Precision Medicine for Treatment of Patients with Cancer from the Marche Region, in Italy [0.03%]
分子肿瘤委员会的影响和绩效：意大利马尔凯地区针对癌症患者的精准医疗三年活动报告
Veronica Agostinelli,Giada Torresi,Valentina Tarantino et al.
Veronica Agostinelli et al.
Introduction: Cancer incidence is rising in Italy, making it harder for researchers to search for innovative and comprehensive treatment strategies. The advancement of precision medicine, the hunt for molecular targets, a...
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib [0.03%]
红细胞分布宽度可预测鲁索利替尼治疗原发性/继发性骨髓纤维化患者所致贫血及预后
Alessandro Laganà,Emilia Scalzulli,Ida Carmosino et al.
Alessandro Laganà et al.
Introduction: Myelofibrosis (MF) is often characterized by a multifactorial anemia determined, in part, by bone marrow (BM) fibrosis, extramedullary erythropoiesis and splenomegaly. Ruxolitinib (RUX) is the first-in-class...
Aggressive Subtypes of Laryngeal Chondrosarcoma and their Clinical Behavior: A Systematic Review [0.03%]
喉软骨肉瘤侵袭性亚型及其临床行为的系统评价
Cesare Piazza,Claudia Montenegro,Michele Tomasoni et al.
Cesare Piazza et al.
Introduction: Laryngeal chondrosarcoma (CS) is a rare indolent malignant tumor. High-grade (G3), dedifferentiated (DD), and myxoid (MY) CSs are considered more aggressive subtypes due to their metastatic potential and rel...